Elena Ridloff, CFO and CBO of Sionna Therapeutics, Inc. (NASDAQ:SION), filed a Form 4 on September 18, 2026, disclosing two restricted stock unit grants and a stock option repricing that took effect on September 17, 2026.
Key Highlights
- Time-based RSU grant: Ridloff received 47,269 RSUs on September 17, 2026, at $0.00 cost, vesting on June 17, 2027, subject to continued service.
- Performance-based RSU grant: An additional 47,268 RSUs were granted on the same date, vesting upon achievement of a designated performance milestone, also subject to continued service.
- Beneficial ownership after grants: Following the two grants, Ridloff directly owned 133,069 shares of common stock.
- Option repricing: A non-qualified stock option covering 165,440 shares had its exercise price reduced from $39.21 to $7.18 per share, representing the fair market value on September 17, 2026 (the "Repricing Date").
- Retention period on repriced option: If the option is exercised before the retention period ends, the exercise price reverts to the original $39.21; the retention period ends on the earliest of March 17, 2028, a Sale Event, or certain qualifying terminations of service.
- Exemption cited: The repricing transactions were reported as exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
RSU Awards and Stock Option Repricing Details for Sionna Therapeutics CFO
According to the filing, Elena Ridloff, serving as CFO and CBO of Sionna Therapeutics, Inc., received two separate restricted stock unit grants on September 17, 2026. The first grant of 47,269 RSUs is time-based and scheduled to vest on June 17, 2027, contingent on her continued service. The second grant of 47,268 RSUs is performance-based, vesting upon the achievement of a designated performance milestone, also subject to her continued service with the issuer as of the vesting date. Each RSU, per the filing, "represents a contingent right to receive one share of Common Stock of the Issuer." Both grants were acquired at a price of $0.00.
The filing also discloses that the issuer's board of directors approved a repricing of an existing non-qualified stock option covering 165,440 shares. The exercise price was reduced from $39.21 to $7.18 per share, the latter representing the fair market value of the issuer's common stock on the Repricing Date. The filing states that "unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price." All other terms of the option remain unchanged, according to the filing.
Following the two RSU grants, Ridloff's direct beneficial ownership of common stock stood at 133,069 shares, per the filing. The repriced option, expiring January 1, 2036, was reported with a resulting beneficial ownership of 165,440 derivative securities, while the original $39.21 option entry shows zero remaining beneficial ownership following the repricing transaction.
What Was Disclosed
The Form 4 filed September 18, 2026, reports two RSU grants totaling 94,537 shares and a board-approved repricing of a 165,440-share stock option from $39.21 to $7.18 per share for Sionna Therapeutics CFO and CBO Elena Ridloff, effective September 17, 2026.




Please wait processing your request...